Trial Profile
An open-label multicenter phase II study of neoadjuvant carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamidein in stage II/III Triple negative breast cancer patients.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2017
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 22 Feb 2017 New trial record